12:00 AM
 | 
Aug 05, 2010
 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Endocrine disease
Obesity Cannabinoid CB1 receptor (CNR1) Mouse studies suggest that peripheral CNR1 blockade could help treat obesity and obesity-associated metabolic...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >